Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis, venous thromboembolic events (VTEs), and arte...
Saved in:
| Main Authors: | Yachar Dawudi, Samuel Benarroch, Hélène Helfer, David M. Smadja, Isabelle Mahé |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037924003625 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rheumatoid arthritis and venous thromboembolic events
by: M. A. Satybaldyeva
Published: (2016-10-01) -
Pediatric venous thromboembolism: incidence and patient profile in a single Brazilian institution
by: Liana Ariel de Siqueira Lira, et al.
Published: (2024-11-01) -
Aspirin for the extended prevention of venous thromboembolism: a meta-analysis and trial sequential analysis
by: Michele Carron, et al.
Published: (2025-05-01) -
Risk factors for venous thromboembolic events in patients with rheumatoid arthritis
by: M. A. Satybaldyeva, et al.
Published: (2016-10-01) -
Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism
by: Magnus S. Edvardsen, et al.
Published: (2025-01-01)